HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ogalvibart

Also Known As:

BMS-986414; BMS986414; C135 LS; C135-LS

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	ACTIV-2/A5401 Study Team: 1 article (01/2024)
2.	Caskey, Marina: 1 article (01/2024)
3.	Chew, Kara W: 1 article (01/2024)
4.	Corado, Katya C: 1 article (01/2024)
5.	Currier, Judith S: 1 article (01/2024)
6.	Daar, Eric S: 1 article (01/2024)
7.	Eron, Joseph J: 1 article (01/2024)
8.	Fletcher, Courtney V: 1 article (01/2024)
9.	Giganti, Mark J: 1 article (01/2024)
10.	Hughes, Michael D: 1 article (01/2024)

Related Diseases

1.

01/01/2024 - "ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk for progression were randomized 1:1 to subcutaneously administered BMS-986414 (C135-LS) 200 mg, plus BMS-986413 (C144-LS) 200 mg, (BMS mAbs), or placebo. "
01/01/2021 - "The rhesus macaque model of COVID-19 was utilized to test the added benefit of combinatory parenteral administration of two high-affinity anti-SARS-CoV-2 monoclonal antibodies (mAbs; C144-LS and C135-LS) expressly developed to neutralize the virus and modified to extend their pharmacokinetics. "
01/01/2021 - "We investigated the therapeutic efficacy of a combination of two potent monoclonal antibodies, C135-LS and C144-LS that carry half-life extension mutations, in the rhesus macaque model of COVID-19. "
01/01/2024 - "Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	crexavibart